托珠单抗治疗COVID-19导致继发感染风险的Meta分析OACSTPCD
A Meta-analysis of the Risk of Secondary Infection of Tocilizumab in the Treatment of COVID-19
目的 通过Meta分析评估托珠单抗(tocilizumab,TCZ)治疗新型冠状病毒感染(corona virus disease 2019,COVID-19)导致的继发感染风险,为托珠单抗在COVID-19 患者中应用的安全性提供循证依据.方法 在The Cochrane Library、PubMed、Web of Science、中国知网、中国生物医学文献数据库以及万方数据库中检索了2019 年 12 月 19 日至 2022 年 12 月 …查看全部>>
Objective Meta-analysis was conducted to assess the risk of secondary infection caused by tocilizumab(TCZ)in the treatment of Corona Virus Disease 2019(COVID-19),in order to provide an evidence-based basis for the safety of tocilizumab in patients with COVID-19.Methods Cochrane Library,PubMed,Web of Science,CNKI,SinoMed and Wanfang databases were searched in computer to collect randomized controlled trial and cohort study of treating COVID-19 with tocilizuma…查看全部>>
罗娅;余彦廷;张雪;王重娟
大理大学药学院,云南 大理 671013昆明市第三人民医院急诊科,云南 昆明 650051昆明医科大学附属延安医院药学部,云南 昆明 650051昆明医科大学附属延安医院药学部,云南 昆明 650051
临床医学
托珠单抗COVID-19继发感染Meta分析
TocilizumabCOVID-19Secondary infectionMeta-analysis
《昆明医科大学学报》 2024 (2)
57-64,8
国家自然科学基金资助项目(82060744)
评论